In contrast, the half‐life of the TRIM65 protein in HCC cells under treatment with PUGNAc, an inhibitor of O‐GlcNAcase, was markedly prolonged (Figure 1I; Figure S1E, Supporting Information). This evidence concerns the gene TRIM65 and hepatocellular carcinoma.